Reuters logo
Roche declines comment on Illumina interest
October 16, 2012 / 6:35 AM / in 5 years

Roche declines comment on Illumina interest

ZURICH (Reuters) - Swiss drugmaker Roche Holding AG declined to comment on Tuesday on market talk it might reconsider its bid for U.S. gene-sequencing company Illumina.

Chief Executive Severin Schwan told a conference call for journalists he would not comment on market rumors.

Roche dropped a $6.8 billion hostile takeover bid for the company in April after shareholders blocked its move to gain seats on the company’s board.

Earlier on Tuesday, Roche reported third-quarter sales rose 15 percent to 11.271 billion Swiss francs ($12.07 billion), beating the average analyst forecast of 11.124 billion francs in a Reuters poll.

($1 = 0.9341 Swiss francs)

Reporting by Caroline Copley

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below